In a prespecified secondary analysis of FINEARTS-HF (6001 patients with HF and LVEF ≥40%), the EMPEROR-Preserved risk models discriminated well, and baseline risk did not modify finerenone's effect on HF hospitalisation or CV death (P interaction=.68).
Secondary analysisn = 6,001
Chimura et al. EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HF